| Fund Description |
| ProShares Ultra Nasdaq Biotechnology seeks daily investment results before fees and expenses that correspond to twice (200%) the daily performance of the NASDAQ Biotechnology Index. |
| Fund Profile |
| Fund Name |
ProShares Ultra Nasdaq Biotechnology |
| Fund Exchange Ticker |
BIB |
| Fund Sponsor |
ProShares |
| Fund ISIN |
US74347R2141 |
| Net Expense Ratio |
0.95 % |
| Fund Inception Date |
7 April 2010 |
| Fund Legal Structure |
ETF (Open end fund) |
| Exchange |
NASDAQ |
| Listing Country Code |
US |
| Fund Investment Objective |
| ETF Type Specific |
Equity - Leveraged / Inverse |
| Asset Class |
Equities (Stocks) |
| Index Linked |
Passive |
| Index Name |
Nasdaq Biotech Index |
| Index Provider |
Nasdaq |
| Currency Hedged |
No |
| Inverse / Leveraged |
Leveraged (2x) |
| Developed / Emerging |
Developed Market Funds |
| Market Capitalization Range |
Broad Market / Multi-Cap |
| Growth Value |
Core / Blend |
| Continent |
North America |
| Key Statistics |
| Return As of Date |
1 December 2023 |
| Asset Under Management |
76.82 Million (USD) |
| 1 Month Total Return |
5.26 % |
| Year To Date Return |
-19.42 % |
| 1 Year Total Return |
-2.75 % |
| 3 Year Annualized Total Return |
-14.42 % |
| NAV |
46.5555 |
| Share Outstanding |
1,650,000 |